Lymphoma & Myeloma Clinical Trials
Last Updated: 05/13/2021
CAR T/Cellular Therapy
Lymphoma CAR T/Cellular Therapy
Newly Diagnosed
2018-0580 (ZUMA-12): A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)
Previously Treated
2019-0940 (Zuma 18): A Multicenter, Open-label, Expanded Access Study of KTE-X19 for the Treatment of Subjects with Relapsed/Refractory B-Cell Malignancies
2019-0776 (PBCAR20A): A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Study Participants with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2018-1134 (LOXO-305): A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin's Lymphoma (NHL)
2018-1049 (ALLO-501): Phase I/II study of ALLO-501, an anti-CD19 allogeneic CAR T cell therapy in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma
2017-0730 ( JCAR017): An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
2017-0055 (ZUMA-5): A Phase 2 Multicenter Study of axicabtagene ciloleucel in subjects with relapsed/refractory indolent non-hodgkin lymphoma
2015-0529 (CAR T-cells): Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
2020-0184 (ALLO647): A Single arm, open label, phase 1/2 study evaluating the safety, efficacy, and cellular kinetics/pharmacodynamics of allo-501A, Anti-CD19 allogeneic car t cell therapy, and allo-647, an anti-CD42 monoclonal antibody, in subjects with relapsed/refractor
2020-1137 (CD20): A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (?d) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2
Myeloma CAR T/Cell Therapy
Previously Treated
2018-0639 (KarMMA-3 BB2121): A Phase 3 Multicenter, Randomized, Open-Label Study to Compare Efficacy and Safety of BB2121 vs DARATUMUMAB (DARA) IN COMBINATION WITH POMALIDOMIDE (POM) AND LOW-DOSE DEXAMETHASONE (DEX) (DPd) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) (KarMMa-3)
2018-0572 (KarMMa-2): A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)
2017-1012 (AMG701): A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
2017-0494 (UCARTCS1): Phase I, Open Label Dose-Escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of A Single Dose of UCARTCS1 (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients with Relapse
2017-0444 (P-BCMA-101): Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)
Lymphoma Clinical Trials
Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)
Newly Diagnosed
2017-0859 (ILyAD Vit D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-Free Survival in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy
Previously Treated
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2019-0441 (Imbrella B): An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (Imbrella B)
2019-0313 (CG-806): A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2017-1063 (LAM-002A): A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (apilimod dimesylate capsules) Administered Orally in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase I/Ib Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia
2017-0946 : Long-Term Follow-Up Protocol For Subjects Treated With Gene-Modified T Cells
2020-0863 (CS1001): A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects with Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma
2018-0705 (BTCT4465): A Phase I Dose Escalation and Expanded Cohort Study Of PF-06821497 IN THE Treatment of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL)
2020-0272 (BTCT4465): A phase 1B/3 double-blind, randomized, active-contrlled, 3-stage, biomarker adaptive study of taxemetostat or placebo in combination with lenalidomide plus rituximb in subjects with relapsed/refractor follicular lymphoma
2020-0177 (SWOGS1608): Randomized Phase II Trial In Early Relapsing Or Refractory Follicular Lymphoma
2020-0502 : An Observational Study to Evaluate A Wearable Temperature Monitoring Device in Subjects Receiving CAR - T Therapy
2020-0660 (EAP): Expanded access protocol (EAP) for patients receiving lisocabtagene maraleucel that is nonconforming for commercial release.
2020-1041 (ANTLER): A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)
2016-0641 (MK-3475): Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) In Subjects with Relapsed Follicular Lymphoma
2019-1250 (JCar017): A Phase II, open-label, single arm, multi cohort, multi center trial to evaluate the efficacy and safety of JCar017 in adult subjects with relapsed or refractory indolent B-cell non-hodgkin
2020-0293 (GEN3009): Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma “A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts
2019-0925 : Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in a Precision BioSciences, Inc., Clinical Study
2020-0452 (MALTI1) : Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in a Precision BioSciences, Inc., Clinical Study
2017-0064 (BTK) : A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
2020-0686 : A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-cell Lymphoma
2020-1029 : A Phase 1B Trial of Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (= 65) Patients with Primary CNS Lymphoma
2019-0615 (FT516): A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
2017-0224 (Ibrutinib): Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
2019-0956 (CC-95251) : A Phase 1, Open-Label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed against SIRPa, Alone and in Combination with Cetuximab or Rituximab in Subjects with Advanced Solid and Hematologic Cancers
2019-1132 (FT596): A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
2019-1051 : Pilot study of anakinra to mitigate CAR-T toxicity in subjects with relapsed or refractory large B-cell lymphoma
2020-0639 (AZD4573) : A Modular Phase I/II, Open-label, Multicentre Study to AssessAZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies
2020-0034 (aR2): A Phase II Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Newly Diagnosed
2018-0817 (Mosunetuzumab): A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of MOSUNETUZUMAB (BTCT4465A) in Combination with CHOP or CHPPOLATUZUMAB VEDOTIN in Patients with BCell NHL
Previously Treated
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2019-0605 (CPI-613): A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0999 (Hu5F9-G4): A Phase 1b/2 Trial of Hu5F9 G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0510 (NIVO): Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma
2017-0626 (ASTX660): Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase 1 Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A, With or Without Single-dose Obinutuzumab Pre-treatment, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
2015-0569 (Based CD19): Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
2014-0539 (ACP-196): Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) In Subjects with Relapsed Follicular Lymphoma
2019-1249 (First MIND): A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) – First-MIND
2019-0441 (Imbrella B): An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (Imbrella B)
Hodgkin Lymphoma
Newly Diagnosed
2019-1153 (SWOGS1826): A phase III, randomized study of nivolumab (OPDIVO) plus AVD or BRENTUXIMAB VEDOTIN (ADCETRIS) plus AVD in patients (AGE >/= 12 YEARS) with newly diagnosed advanced stage classical hodgkins lymphoma.
2020-0460 (CD30.CAR-T): A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients with Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma
Previously Treated
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0981 (CD30 - PTCL): A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)
2017-0731 (PD-1 + ICE): A phase II trial of response-adapted second-line therapy for Hodgkin lymphoma using anti-PD-1 antibody nivolumab +/- ICE chemotherapy as a bridge to autologous hematopoietic cell transplant (NICE Trial)
2019-0318 (cHL): A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
2020-0085 (PTCL): A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
2018-0114 (DVD-AVD): A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin plus Nivolumab, Followed by Nivolumab Consolidation for Patients with Previ
Mantle Cell Lymphoma
Newly Diagnosed
2018-0447 (Young MCL Pts): A Phase II Study of Ibrutinib plus Rituximab followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma: Window II Protocol
2016-1048 (ACP-196): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Verses in Combination with Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Previously Treated
2019-0123 (HMPL-523): A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
2019-0421 (ACAL): A Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Mantle Cell Lymphoma
2019-0469 (BGB-3111): A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
2012-1107 (PCI-32765): A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
2016-0914 (Ib-Smol): A Phase II Trial of Ibrutinib in previously untreated high risk smoldering mantle cell lymphoma (MCL)
2019-0922 (ICP-022): A Phase I, Multicenter, Open-Label, Dose EscalationStudy of a Novel BrutonÂfs Tyrosine Kinase Inhibitor,ICP-022, in Patients with Relapsed/Refractory B-Cell
2019-1022 (Match): A Pilot Study of Interrogating biological Signaling Pathways Dysregulations and in vitro Screening with Personalized Therapies in resistant Mantle Cell Lymphoma (MCL) - the MCL Match Trial
2020-0638 (BGB-3111): An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B cell malignancies
2020-0858 (Acal-Rit): A Phase II Study of Acalabrutinib plus rituximab in previously untreated elderly patients with Mantle Cell Lymphoma
2018-0996 (VLS-101): A Phase 1 dose-escalation and cohort-expansion study of VLS-101 in subjects with Hematological Malignancies
2018-0935 (Venetoclax & Acalabrutinib): An open label, Phase II investigator initiated study of venetoclax and acalabrutinib in previously treated relapsed/refractory patients with mantle cell lymphoma (MCL)
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0051 (PDX): A Pilot Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response: The EXPLORE trial
2020-1242 (LOXO-305): A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
2016-0024 (ACP-196): A Phase 1b, Multicenter, Open-label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma
2015-0663 (BGB-3111): A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies
2014-0559 (Rit+H-CVAD): A Phase II Study of Ibrutinib plus Rituximab with Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy before Chemotherapy
2014-0630 (ONC201): Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Burkitt's Lymphoma
Newly Diagnosed
2018-0817 (Mosunetuzumab): A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of MOSUNETUZUMAB (BTCT4465A) in Combination with CHOP or CHPPOLATUZUMAB VEDOTIN in Patients with BCell NHL
Previously Treated
2019-0644 (IGM-2323): Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma
2018-0999 (Hu5F9): A Phase 1b/2 Trial of Hu5F9 G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
2017-0141 (BTCT4465): An Open-label, Multicenter, Phase 1 Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A, With or Without Single-dose Obinutuzumab Pre-treatment, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
2014-0539 (ACP-196): Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) In Subjects with Relapsed Follicular Lymphoma
Peripheral T-Cell Lymphoma
Newly Diagnosed
2017-0927 (CD30+ PTCL): A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas
Previously Treated
2019-0755 (REDIRECT): A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
2017-0272 (MK-3475): A Phase I/II Study of Pembrolizumab (MK-3475) in Combination with Romidepsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
2018-0908 (RP6530): An Open label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor Given in Combination with a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients with Relapsed/Refractory T-cell Lymphoma
2018-1064 (TTI-622): A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advance Relapsed or Refractory Lymphoma or Myeloma
2019-1082 (RP6530): An Open label, Compassionate Use Study of Tenalisib (RP6530) in Patients currently receiving treatment on Tenalisib trials in Hematological Malignancies
2020-0238 (CTX130): A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refractory T or B Cell Malignancies
Multiple Myeloma Clinical Trials
Myeloma CAR T/Cellular Therapy
Myeloma
Newly Diagnosed
2019-0556 (TAK-079): An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
2019-0304 (NDMM): A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
2018-0345 (Vaccine in SMM): A Personalized Vaccine for the Immune Prevention of Multiple Myeloma
Previously Treated
2019-0945 (REGN5459): A Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
2019-0452 (RRMM): A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
2020-0464 (CAEL-101): Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amylo
2020-0472 (CAEL-101 Amy): A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amy
2018-1102 (D-VRd): A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2015-0148 : Phase II Trial Of Isatuximab With or Without Lenalidomide In Patients With High Risk Smoldering Multiple Myeloma
2020-0720 : A Non-Interventional, Multinational, Observational Study with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
2019-0499 (CT053): Open label, multi-center, phase 1b clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
2019-0624 (NKTR-255): A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
2018-0710 (P-BCMA-101): Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101
2018-0639 (BB2121): A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)
2018-0572 (BB2121): A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of BB2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma having Progressed within One Year of In
2019-1090 (NDMM): A Phase I, Open-label, Multicenter Study to Evaluate the Safety of BB2121 in Subjects with High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
2020-0146 (PBCAR269A):A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, with or without nirogacestat, in Study Subjects with Relapsed/Refractory Multiple Myeloma
2020-0113 (MYD88):A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenstrom Macroglobulinemia (WM) whose Tumors Express Mutations in MYD88 and CXCR4
2020-0534 (APG-2575):A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenstrom Macroglobulinemia (WM)
2020-0103 (BFCR4350A):An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of BFCR4350A In Patients With Relapsed Or Refractory Multiple Myeloma
2020-0610 (ION-251): A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma
2018-0512 (D+B-Dex in R/R MM): A Phase 2 Study of Daratumumab, Bortezomab and Dexamethasone followed by Daratumumab, Ixaazomib, and Dexamethasone for Relapsed/Refractory Myeloma
2018-0285 (Ventelocla): A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11 14)-Positive Relapsed or Refractory Multiple Myeloma
2018-0192 (XmAb13676): A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients with CD20-Expressing Hematologic Malignancies
2017-0618 (CC-92480 +Dex in R/R MM): A Phase I Multicenter, Open-label study to assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
2017-0243 (AL AMY): A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
2016-0225 (c-Met Inh): A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma
2014-0729 (Elotuzumab + Lenalidomide): Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
NCI10076 (AM232): A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Lab10-0774 : Genome Wide Admixture Scan of Multiple Myeloma in African-Americans